Page 1 of 63
PHARMACOLOGY QUESTIONS AND CORRECT ANSWERS LATEST EDITION
Pharmacology Exam: 250 MCQs
1. Which of the following pharmacokinetic processes involves the movement of a
drug from its site of administration into the systemic circulation?
A. Distribution
B. Metabolism
C. Absorption
D. Excretion
Rationale: Absorption is the process by which a drug moves from its site of
administration into the bloodstream. Distribution is the movement from blood to
tissues. Metabolism is the breakdown of the drug. Excretion is the removal of the drug
from the body.
2. A patient with severe renal impairment is prescribed a drug that is primarily
excreted unchanged by the kidneys. What pharmacokinetic parameter is most
likely to be significantly prolonged?
A. Bioavailability
B. Half-life
C. Volume of distribution
D. Protein binding
Rationale: The half-life of a drug is the time it takes for the plasma concentration to
reduce by 50%. If renal excretion is impaired, the drug will remain in the body longer,
significantly prolonging its half-life and increasing the risk of toxicity.
3. Which of the following terms describes the fraction of an administered dose of
a drug that reaches the systemic circulation unchanged?
A. Bioavailability
B. Clearance
C. Volume of distribution
D. Therapeutic index
Rationale: Bioavailability is a measure of the rate and extent of the drug reaching the
1|Page
,Page 2 of 63
systemic circulation. An intravenous dose has 100% bioavailability, while oral
bioavailability can be reduced by first-pass metabolism.
4. What is the primary mechanism of action for drugs that act as competitive
antagonists at a receptor site?
A. They bind to the receptor and activate a downstream signaling cascade.
B. They bind to the receptor and prevent the agonist from binding and activating it.
C. They bind to an allosteric site and enhance the agonist's effect.
D. They inhibit the enzyme responsible for breaking down the agonist.
Rationale: A competitive antagonist binds reversibly to the same receptor site as the
agonist. This prevents the agonist from binding and exerting its effect, but the blockade
can be overcome by increasing the concentration of the agonist.
5. Which of the following drug properties is primarily determined by the drug's
lipid solubility and ionization state at physiological pH?
A. Receptor affinity
B. Intrinsic activity
C. Ability to cross cell membranes
D. Rate of renal excretion
Rationale: Lipid-soluble, non-ionized drugs can easily cross the lipid bilayer of cell
membranes. Ionized drugs are less lipid-soluble and are generally unable to cross
membranes easily, which affects their absorption, distribution, and excretion.
6. A drug that binds to a receptor and produces a maximal response, similar to the
endogenous ligand, is best described as which type of agent?
A. Partial agonist
B. Competitive antagonist
C. Full agonist
D. Inverse agonist
Rationale: A full agonist has both high affinity for the receptor and high intrinsic
activity, meaning it can produce a maximal biological response. A partial agonist
produces a submaximal response even at full receptor occupancy.
7. Which of the following routes of drug administration bypasses the hepatic first-
pass metabolism entirely?
A. Oral
B. Rectal
C. Sublingual
D. Enteric-coated oral
Rationale: Sublingual administration involves placing the drug under the tongue, where
2|Page
,Page 3 of 63
it is absorbed directly into the systemic venous circulation, bypassing the portal vein and
the liver. This avoids first-pass metabolism.
8. The therapeutic index of a drug is a measure of its safety and is calculated by
which of the following ratios?
A. ED50 / LD50
B. LD50 / ED50
C. TD50 / ED50
D. ED50 / TD50
Rationale: The therapeutic index is the ratio of the median lethal dose (LD50) to the
median effective dose (ED50). A higher therapeutic index indicates a wider margin of
safety between therapeutic and toxic doses.
9. Which of the following statements accurately describes the phenomenon of
zero-order elimination kinetics?
A. A constant fraction of the drug is eliminated per unit of time.
B. A constant amount of the drug is eliminated per unit of time.
C. The rate of elimination is proportional to the plasma concentration.
D. The drug is eliminated exclusively by the kidneys.
Rationale: In zero-order kinetics, the metabolic or excretory pathways are saturated.
Therefore, the rate of elimination is constant and independent of the drug's plasma
concentration. A classic example is ethanol.
10. Which of the following is a major characteristic of a non-competitive
antagonist?
A. It can be overcome by increasing the agonist concentration.
B. It binds to the same site as the agonist.
C. It reduces the maximal efficacy of the agonist.
D. It increases the potency of the agonist.
Rationale: A non-competitive antagonist binds to a site other than the agonist binding
site (allosteric) or irreversibly to the active site. This reduces the maximal effect (efficacy)
that the agonist can produce, and this effect cannot be overcome by adding more
agonist.
11. Which of the following drugs is a direct-acting cholinergic agonist primarily
used to treat glaucoma and urinary retention?
A. Atropine
B. Bethanechol
C. Neostigmine
D. Pralidoxime
Rationale: Bethanechol is a direct-acting muscarinic agonist. It stimulates the bladder
3|Page
, Page 4 of 63
and GI tract, making it useful for postoperative urinary retention and certain types of
glaucoma by causing pupil constriction.
12. A patient is given a drug that causes bradycardia, miosis, and increased
salivation. This drug is most likely a member of which pharmacological class?
A. Adrenergic agonist
B. Muscarinic agonist
C. Nicotinic antagonist
D. Adrenergic antagonist
Rationale: These symptoms are classic signs of parasympathetic (cholinergic)
stimulation. A muscarinic agonist would cause bradycardia (decreased heart rate), miosis
(pupil constriction), and increased salivation.
13. Which of the following is the primary mechanism of action of
organophosphate insecticides, leading to their toxic effects?
A. Direct stimulation of nicotinic receptors
B. Irreversible inhibition of acetylcholinesterase
C. Blockade of muscarinic receptors
D. Inhibition of acetylcholine release
Rationale: Organophosphates irreversibly inhibit acetylcholinesterase, the enzyme that
breaks down acetylcholine. This leads to an accumulation of acetylcholine at synapses,
causing excessive cholinergic stimulation.
14. Atropine is a muscarinic antagonist used to treat organophosphate poisoning.
Which of the following effects would it be expected to reverse?
A. Skeletal muscle fasciculations
B. Excessive salivation and lacrimation
C. Central nervous system depression
D. Nicotinic receptor overstimulation
Rationale: Atropine blocks muscarinic receptors, reversing the parasympathetic effects
of excess acetylcholine such as bradycardia, salivation, lacrimation, and urination. It does
not affect nicotinic receptors, so it won't reverse skeletal muscle effects.
15. Which of the following neuromuscular blocking agents acts as a depolarizing
blocker, causing initial fasciculations before paralysis?
A. Tubocurarine
B. Pancuronium
C. Succinylcholine
D. Vecuronium
Rationale: Succinylcholine binds to nicotinic receptors at the neuromuscular junction
4|Page
PHARMACOLOGY QUESTIONS AND CORRECT ANSWERS LATEST EDITION
Pharmacology Exam: 250 MCQs
1. Which of the following pharmacokinetic processes involves the movement of a
drug from its site of administration into the systemic circulation?
A. Distribution
B. Metabolism
C. Absorption
D. Excretion
Rationale: Absorption is the process by which a drug moves from its site of
administration into the bloodstream. Distribution is the movement from blood to
tissues. Metabolism is the breakdown of the drug. Excretion is the removal of the drug
from the body.
2. A patient with severe renal impairment is prescribed a drug that is primarily
excreted unchanged by the kidneys. What pharmacokinetic parameter is most
likely to be significantly prolonged?
A. Bioavailability
B. Half-life
C. Volume of distribution
D. Protein binding
Rationale: The half-life of a drug is the time it takes for the plasma concentration to
reduce by 50%. If renal excretion is impaired, the drug will remain in the body longer,
significantly prolonging its half-life and increasing the risk of toxicity.
3. Which of the following terms describes the fraction of an administered dose of
a drug that reaches the systemic circulation unchanged?
A. Bioavailability
B. Clearance
C. Volume of distribution
D. Therapeutic index
Rationale: Bioavailability is a measure of the rate and extent of the drug reaching the
1|Page
,Page 2 of 63
systemic circulation. An intravenous dose has 100% bioavailability, while oral
bioavailability can be reduced by first-pass metabolism.
4. What is the primary mechanism of action for drugs that act as competitive
antagonists at a receptor site?
A. They bind to the receptor and activate a downstream signaling cascade.
B. They bind to the receptor and prevent the agonist from binding and activating it.
C. They bind to an allosteric site and enhance the agonist's effect.
D. They inhibit the enzyme responsible for breaking down the agonist.
Rationale: A competitive antagonist binds reversibly to the same receptor site as the
agonist. This prevents the agonist from binding and exerting its effect, but the blockade
can be overcome by increasing the concentration of the agonist.
5. Which of the following drug properties is primarily determined by the drug's
lipid solubility and ionization state at physiological pH?
A. Receptor affinity
B. Intrinsic activity
C. Ability to cross cell membranes
D. Rate of renal excretion
Rationale: Lipid-soluble, non-ionized drugs can easily cross the lipid bilayer of cell
membranes. Ionized drugs are less lipid-soluble and are generally unable to cross
membranes easily, which affects their absorption, distribution, and excretion.
6. A drug that binds to a receptor and produces a maximal response, similar to the
endogenous ligand, is best described as which type of agent?
A. Partial agonist
B. Competitive antagonist
C. Full agonist
D. Inverse agonist
Rationale: A full agonist has both high affinity for the receptor and high intrinsic
activity, meaning it can produce a maximal biological response. A partial agonist
produces a submaximal response even at full receptor occupancy.
7. Which of the following routes of drug administration bypasses the hepatic first-
pass metabolism entirely?
A. Oral
B. Rectal
C. Sublingual
D. Enteric-coated oral
Rationale: Sublingual administration involves placing the drug under the tongue, where
2|Page
,Page 3 of 63
it is absorbed directly into the systemic venous circulation, bypassing the portal vein and
the liver. This avoids first-pass metabolism.
8. The therapeutic index of a drug is a measure of its safety and is calculated by
which of the following ratios?
A. ED50 / LD50
B. LD50 / ED50
C. TD50 / ED50
D. ED50 / TD50
Rationale: The therapeutic index is the ratio of the median lethal dose (LD50) to the
median effective dose (ED50). A higher therapeutic index indicates a wider margin of
safety between therapeutic and toxic doses.
9. Which of the following statements accurately describes the phenomenon of
zero-order elimination kinetics?
A. A constant fraction of the drug is eliminated per unit of time.
B. A constant amount of the drug is eliminated per unit of time.
C. The rate of elimination is proportional to the plasma concentration.
D. The drug is eliminated exclusively by the kidneys.
Rationale: In zero-order kinetics, the metabolic or excretory pathways are saturated.
Therefore, the rate of elimination is constant and independent of the drug's plasma
concentration. A classic example is ethanol.
10. Which of the following is a major characteristic of a non-competitive
antagonist?
A. It can be overcome by increasing the agonist concentration.
B. It binds to the same site as the agonist.
C. It reduces the maximal efficacy of the agonist.
D. It increases the potency of the agonist.
Rationale: A non-competitive antagonist binds to a site other than the agonist binding
site (allosteric) or irreversibly to the active site. This reduces the maximal effect (efficacy)
that the agonist can produce, and this effect cannot be overcome by adding more
agonist.
11. Which of the following drugs is a direct-acting cholinergic agonist primarily
used to treat glaucoma and urinary retention?
A. Atropine
B. Bethanechol
C. Neostigmine
D. Pralidoxime
Rationale: Bethanechol is a direct-acting muscarinic agonist. It stimulates the bladder
3|Page
, Page 4 of 63
and GI tract, making it useful for postoperative urinary retention and certain types of
glaucoma by causing pupil constriction.
12. A patient is given a drug that causes bradycardia, miosis, and increased
salivation. This drug is most likely a member of which pharmacological class?
A. Adrenergic agonist
B. Muscarinic agonist
C. Nicotinic antagonist
D. Adrenergic antagonist
Rationale: These symptoms are classic signs of parasympathetic (cholinergic)
stimulation. A muscarinic agonist would cause bradycardia (decreased heart rate), miosis
(pupil constriction), and increased salivation.
13. Which of the following is the primary mechanism of action of
organophosphate insecticides, leading to their toxic effects?
A. Direct stimulation of nicotinic receptors
B. Irreversible inhibition of acetylcholinesterase
C. Blockade of muscarinic receptors
D. Inhibition of acetylcholine release
Rationale: Organophosphates irreversibly inhibit acetylcholinesterase, the enzyme that
breaks down acetylcholine. This leads to an accumulation of acetylcholine at synapses,
causing excessive cholinergic stimulation.
14. Atropine is a muscarinic antagonist used to treat organophosphate poisoning.
Which of the following effects would it be expected to reverse?
A. Skeletal muscle fasciculations
B. Excessive salivation and lacrimation
C. Central nervous system depression
D. Nicotinic receptor overstimulation
Rationale: Atropine blocks muscarinic receptors, reversing the parasympathetic effects
of excess acetylcholine such as bradycardia, salivation, lacrimation, and urination. It does
not affect nicotinic receptors, so it won't reverse skeletal muscle effects.
15. Which of the following neuromuscular blocking agents acts as a depolarizing
blocker, causing initial fasciculations before paralysis?
A. Tubocurarine
B. Pancuronium
C. Succinylcholine
D. Vecuronium
Rationale: Succinylcholine binds to nicotinic receptors at the neuromuscular junction
4|Page
